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Abstract
Background: The Global initiative for chronic Obstructive Lung Disease (GOLD) defines COPD as a fixed post-
bronchodilator ratio of forced expiratory volume in 1 second and forced vital capacity (FEV1/FVC) below 0.7. Age-
dependent cut-off values below the lower fifth percentile (LLN) of this ratio derived from the general population
have been proposed as an alternative. We wanted to assess the diagnostic accuracy and prognostic capability of
the GOLD and LLN definition when compared to an expert-based diagnosis.
Methods: In a prospective cohort study, 405 patients aged ≥ 65 years with a general practitioner’s diagnosis of
COPD were recruited and followed up for 4.5 (median; quartiles 3.9; 5.1) years. Prevalence rates of COPD according
to GOLD and three LLN definitions and diagnostic performance measurements were calculated. The reference
standard was the diagnosis of COPD of an expert panel that used all available diagnostic information, including
spirometry and bodyplethysmography.
Results: Compared to the expert panel diagnosis, ‘GOLD-COPD’ misclassified 69 (28%) patients, and the three LLNs
misclassified 114 (46%), 96 (39%), and 98 (40%) patients, respectively. The GOLD classification led to more false
positives, the LLNs to more false negative diagnoses. The main predictors beyond the FEV1/FVC ratio for an expert
diagnosis of COPD were the FEV1 % predicted, and the residual volume/total lung capacity ratio (RV/TLC). Adding
FEV1 and RV/TLC to GOLD or LLN improved the diagnostic accuracy, resulting in a significant reduction of up to
50% of the number of misdiagnoses. The expert diagnosis of COPD better predicts exacerbations, hospitalizations
and mortality than GOLD or LLN.
Conclusions: GOLD criteria over-diagnose COPD, while LLN definitions under-diagnose COPD in elderly patients as
compared to an expert panel diagnosis. Incorporating FEV1 and RV/TLC into the GOLD-COPD or LLN-based
definition brings both definitions closer to expert panel diagnosis of COPD, and to daily clinical practice.
Keywords: COPD diagnosis, lower limit of normal, GOLD, validation
Introduction
Chronic obstructive pulmonary disease (COPD) is among
the leading causes of disability and death in developed
countries. The prevalence of COPD is still on the rise,
and costs for the health system are substantial [1,2].
Airflow limitation that is not fully reversible after
bronchodilator application is a key feature of COPD, and
spirometry is the routine diagnostic procedure of choice
recommended to diagnose COPD [3,4]. However, the
degree of obstruction that establishes the diagnosis of
COPD is still under debate [5]. The Global Initiative for
chronic Obstructive Lung Disease (GOLD) defined
COPD as a fixed post-bronchodilator ratio of forced
expiratory volume in 1 second and forced vital capacity
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any medium, provided the original work is properly cited.(FEV1/FVC ratio) of less than 0.70 [6]. This definition is
widely accepted, mainly because of its practicability.
Since the FEV1 value decreases more quickly with age
than the (F)VC, the GOLD definition tends to overdiag-
nose COPD in the elderly [7,8]. Therefore, some authors
suggested using the lower limit of normal (LLN) proce-
dure to diagnose COPD [5]. The LLN is based on age-
stratified pre-bronchodilator cut-off values of the FEV1/
FVC ratio, and a value below the lower fifth percentile
of an aged-matched healthy reference group is consid-
ered abnormal and consistent with a diagnosis of COPD
[9,10]. Multiple studies showed that application of any
population-derived LLN will result in lower prevalence
estimates of COPD compared to the GOLD definition
in the elderly [5,9]. The question remains however
which method should be preferred. Another question is,
whether there are other pulmonary function test vari-
ables that could improve the diagnostic accuracy of
GOLD or LLN. The final question is, which definition
predicts best prognosis and thus is useful for treatment
decisions in COPD. To answer all three questions, the
two criteria should be compared with an alternative, and
acceptable reference standard, applied in the relevant
domain, that is, a population suspected of COPD [11].
An expert panel diagnosis of COPD, based on all avail-
able diagnostic information from the clinical assessment,
smoking habits, and a complete pulmonary function test
(PFT) could be regarded as such a reference standard
[11].
To the best of our knowledge, our study is the first to
validate GOLD and LLN criteria against an expert panel
diagnosis in patients suspected of COPD and to assess
their prognostic ability.
Since, in daily practice, establishing the diagnosis of
COPD is usually not based on a single PFT parameter,
we furthermore assessed whether the addition of other
PFT parameters to the GOLD or LLN criteria increases
diagnostic accuracy compared to either definition alone.
Methods
Subject and Study Design
In a prospective cohort study, 405 patients aged ≥ 65
years with a general practitioner’s (GP) diagnosis of
COPD were enrolled in a stable phase of their disease.
Primary assessment was between 2001 and 2003. Popu-
lation and study characteristics have been published pre-
viously [12,13]. In brief, all patients underwent a detailed
standardized clinical examination at an outpatient clinic
(University Medical Center Utrecht) including PFT,
chest radiography, and echocardiography. The study
complied with the Declaration of Helsinki, and the Med-
ical Ethical Committee of the University Medical Center
Utrecht approved the study protocol. All participants
gave their written informed consent.
Pulmonary function tests
All PFT were performed with a fixed volume body-
plethysmograph and Masterscreen (Masterlab Jaeger,
Würzburg, Germany). The post-bronchodilator test was
assessed after inhalation of ipratropium bromide (40
micrograms twice). For predicted values of lung function
markers, the recommendations of the European Respira-
tory Society were used [14].
Expert panel diagnosis of COPD
I na b s e n c eo fat r u er e f e r e n c es t a n d a r d ,ac o n s e n s u so f
an expert panel is widely accepted as the best alternative
[11]. The initial expert panel of the study was composed
of a qualified pulmonologist (JWL) and a GP with spe-
cial interest in COPD (FHR). The panel determined pre-
sence or absence of COPD on all available results from
the clinical assessment, including history taking and
smoking history, chest radiographs, and finally spiro-
metric and bodyplethysmographic information (data and
graphs). Besides FEV1/FVC ratio other parameters from
the PFT were also considered, including the shape of
the curve, FEV1 as % predicted, presence of reversibility,
RV/TLC, resistance, air trapping, and DLCO value.
Also, smoking habits, a history of allergy or hyperreac-
tivity, initiation of (periods of) dyspnoea and coughing
at an early age, and a history of pulmonary embolism or
lung diseases other than COPD were used in case of
doubt and when applicable.
The same members of the expert panel re-evaluated
the diagnosis in a random sample of 80 (20%) cases in
2011, resulting in an excellent kappa statistic between
initial and repeat evaluation of 0.90. Another random
sample of 120 (30%) cases was externally validated by a
p a n e lc o m p o s e do faG e r m a np u l m o n o l o g i s t( M H )a n d
a Dutch GP with a special interest in COPD (APS).
Kappa statistic between the initial panel diagnosis and
that of the external panel was 0.76.
Both panels followed the aforementioned ‘strategy’ to
diagnose COPD. Asthma was diagnosed if a reversible
obstruction went along with a typical history of asthma
(allergy, hyperreactivity, onset of symptoms at a young
age). Reversibility was considered present if the FEV1
levels increased by 200 ml and/or 12% after bronchodi-
lator therapy, accordingly to the American Thoracic
society definition [10].
Diagnosis of COPD according to the GOLD and LLN
criteria
A post-bronchodilator FEV1/FVC ratio < 0.70 estab-
lished the diagnosis ‘GOLD-COPD’ [4]. The ‘GOLD-
COPD’ was graded using post-bronchodilator % of pre-
dicted FEV1 values: GOLD stage 1 (mild): ≥ 80%; stage
2 (moderate): 50-79%; stage 3 (severe): 30-49; stage 4
(very severe) < 30% [4].
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healthy reference groups (similar age) established the
diagnosis ‘LLN-COPD’. From several LLN equations
provided by http://www.spirxpert.com/controversies/
workinggroup.html[14-17] we selected three LLN refer-
ence equations on the basis of sample size, popularity
and comparability with the age of our study population.
These equations were derived from the following
populations:
1. Enright et al. [16]: USA; healthy Caucasians with no
respiratory symptoms, N = 1,227, 26% male, age range
65-85 years, non-smokers or all-time smoking duration
< 5 years.
2. Quanjer et al. (ECCS/ERS) [14]: Europe; healthy
never-smokers with no respiratory symptoms, N =
1,204, 27% male, age range 20-70 years.
3. Falaschetti et al. (Health Survey for England) [17]:
Great Britain; healthy never-smokers with no respiratory
disease, N = 6,053, 41% male, age range 16-85 years.
The aforementioned reference equations of the LLN-
COPD definitions are based on pre-bronchodilator
values, and the GOLD-COPD definition on post-
bronchodilatory FEV1/FVC values. We analysed both
pre- and post-bronchodilator cut-off values for both
d e f i n i t i o n s .B e c a u s et h er e s u l t sw e r es i m i l a r ,w eo n l y
present the post-bronchodilator results.
Prognostic outcomes
Exacerbations of COPD (need for short course of oral ster-
oids), hospitalization for COPD, and all-cause mortality
were assessed blinded to the diagnostic classification.
Data analysis
Continuous data are expressed as mean (standard devia-
tion, SD) or median (quartiles), as appropriate. Compari-
sons between groups were made with Fisher’se x a c tt e s t
or Mann-Whitney U-test. Sensitivity, specificity, positive
and negative predictive values and kappa () statistics
with 95% confidence intervals (CI) were calculated for
each COPD definition with the ‘expert panel diagnosis of
COPD’ of the initial panel as the reference test. The clas-
sification system proposed by Landis and Koch was used
to determine the level of concordance (a  of 0.81-1.00 is
considered almost perfect) [18]. A bootstrap method was
used for calculating 95% CI of  and to assess statistical
significance for correlated  [19,20]. The diagnostic abil-
ity of different PFT parameters for predicting COPD
according to the reference standard was tested using
ROC curve with C-statistics with 95% CI [20]. The two
PFT parameters predicting best according to the C-statis-
tics were incorporated into a new ‘modified’ GOLD- or
LLN-based definition, and diagnostic performance (false
positives, false negatives, kappa) of these extended mod-
els were compared to the original definitions (Figure 1).
Prognostic analysis for different outcomes (exacerba-
tion, hospitalization, death) were calculated with univari-
ate Cox regression.
Missing data and statistical analyses
Very few values in the dataset were missing, with the
exception of the diffusion capacity of carbon monoxide
(DLCO) with 42 missings. On residual volume (RV) and
total lung capacity (TLC) we had five missings. As dele-
tion of subjects with missing values may lead to biased
results we imputed missing values using a regression
method with the addition of a random error term [21].
All statistical analyses were carried out using the sta-
tistical software package of SPSS (PASW Statistics 18)
and R for windows (version 2.11.0).
Results
The mean age of patients was 73 (5.3) years, 45% were
female. The baseline characteristics of participants are
shown in table 1 and 2. Table 3 shows the differential
performance of the GOLD approach and of three differ-
ent LLN definitions with the expert panel diagnosis as
the reference test.
In our elderly cohort all regression equations used for
the LLN definition had a lower FEV1/FVC threshold
than the GOLD definition. Specificity was higher and
sensitivity lower for LLN than GOLD. When compared
to the reference test, kappa statistics were higher for
Figure 1 Flow chart for diagnostic algorithm. In clinical practice
the diagnosis of COPD is based on multiple variables. As the
simplest model we chose a three PFT parameters approach in
which an initial COPD YES/NO diagnosis based on FEV/FVC levels
was corrected if FEV1 and RV/TLC levels were altered
counterintuitively*. * As thresholds for FEV1 and RV/TLC levels
different cut-off levels were used and kappa statistics calculated for
all alternatives. Each change in COPD diagnosis only materializes if
both parameters deviate by ≤ 5/7.5/10/12.5/15/20% from 100% of
the predicted value. Example: If deviations of 10% (from 100%) are
chosen as thresholds for both FEV1 and RV/TLC (as % of predicted)
in order to change the GOLD-COPD diagnosis from
1) ’yes’ into ‘no’
(i.e., FEV1 ≥ 90% and RV/TLC ≤ 110%; [
2) or vice versa, from ‘no’ into
‘yes’, FEV1 < 90% and RV/TLC > 110%]), then the number of
misclassified patients (false positives + false negatives) is reduced
from 69 to 33, and - statistics improve from 0.64 to 0.83.
Abbreviations: as in table 1.
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ever not all differences were statistically significant
(table 2).
’Misdiagnosed’ patients with the GOLD definition as
compared to the expert panel
There was reasonable concordance between the diagno-
sis of COPD with the GOLD definition and the expert
panel ( = 0.64, 95% CI 0.57-0.71, table 3). Classification
according to GOLD resulted in 33 false positive and 36
false negative diagnoses as compared to the expert panel
diagnosis of COPD (table 4).
In general, patients with a “true positive COPD diag-
nosis” tend to have RV/TLC values (far) above 100% of
predicted, a FEV1 value (far) below 100% of predicted,
and a DLCO values (far) below 80% of predicted, as
compared to healthy individuals.
In our cohort, the median RV/TLC of patients with
COPD according to the expert panel was high (median
[quartiles]: 124 [112; 140] as % of predicted), median
Table 1 Baseline characteristics of patients with and without COPD according to the expert panel and the GOLD
definition
All Subjects Expert Panel P GOLD definition P
(n = 405) No COPD (n = 158) COPD (n = 247) No COPD (n = 161) COPD (n = 244)
Age, years 72(69; 77) 71.5(67; 76) 73(70; 77) 0.004 72(67; 76) 73(70; 77) 0.010
Male sex, % 55.1 40.5 64.4 < 0.001 34.8 68.4 < 0.001
Death, % 14.9 6.3 20.5 < 0.001 10.6 17.8 0.047
Pack years smoking 16.8 (0; 38.8) 1.5 (0; 23) 27 (8.3; 51) < 0.001 2.3 (0; 28) 25.2 (5.5; 51) < 0.001
BMI, kg/m
2 26.2
(24.1; 28.8)
27
(24.8; 30.1)
25.6
(23.4; 28.3)
< 0.001 27
(24.7; 30)
25.6
(23.3; 28.3)
< 0.001
Comorbidities and Symptoms
Hypertension, % 39.0 42.4 36.8 0.30 46.6 34.0 0.013
Diabetes, % 8.6 8.9 8.5 1.00 9.9 7.8 0.47
Stroke or TIA, % 22.0 17.1 25.1 0.07 18.0 24.6 0.14
Fatigue, % 41.3 46.8 37.8 0.08 46.6 37.9 0.09
Wheezing, % 63.5 55.1 68.8 0.006 59.0 66.4 0.14
COPD Inhalatory Medication
Beta2-mimetics, % 58.2 39.9 69.9 < 0.001 41.6 69.1 < 0.001
Anticholinergics, % 47.6 36.1 55.1 < 0.001 36.0 55.4 < 0.001
Inhaled Corticosteroids, % 63.0 56.3 67.2 0.035 58.4 66.0 0.14
Data are shown as median (25
th;7 5
th percentile) or %, as appropriate. P-value refers to c
2-test or Mann-Whitney-U test as appropriate.
Abbreviations: BMI, body mass index, TIA, transient ischemic attack.
Table 2 Pulmonary function test of patients with and without COPD according to the expert panel and the GOLD
definition
All Subjects Expert Panel P GOLD definition P
(n = 405) No COPD (n = 158) COPD (n = 247) No COPD (n = 161) COPD (n = 244)
Pre-bronchodilator Pulmonary Function Test
FEV1, % 76 (57; 96) 100 (92; 111) 62 (48; 75) < 0.001 99 (84; 110) 63 (48; 79) < 0.001
FVC, % 95 (78; 109) 109 (99; 120) 84 (74; 96) < 0.001 104 (91; 117) 88 (76; 102) < 0.001
FEV1/FVC 0.66 (0.55; 0.74) 0.75 (0.7; 0.8) 0.58 (0.48; 0.66) < 0.001 0.75 (0.71; 0.8) 0.58 (0.48; 0.65) < 0.001
TLC, % 110 (100; 122) 107 (98; 116) 113 (102; 125) < 0.001 105 (97; 114) 114 (104; 125) < 0.001
RV, % 126 (106; 159) 108 (94; 121) 146 (120; 175) < 0.001 108 (96; 126) 142 (117; 174) < 0.001
RV/TLC, % 114 (99; 132) 99 (92; 108) 124 (112; 140) < 0.001 102 (93; 115) 122 (108; 138) < 0.001
DLCO, % 72 (58; 83) 81 (71; 91) 63 (49; 76) < 0.001 78 (67; 89) 66 (50; 79) < 0.001
Post-bronchodilator Pulmonary Function Test
FEV1, % 82 (64; 102) 106 (97; 116) 69 (56; 81) < 0.001 103 (89; 115) 70 (56; 85) < 0.001
FVC, % 102 (88; 117) 114 (103; 125) 92 (80; 108) < 0.001 105 (91; 120) 98 (85; 115) 0.004
FEV1/FVC 0.66 (0.55; 0.75) 0.76 (0.71; 0.81) 0.58 (0.48; 0.66) < 0.001 0.77(0.74; 0.81) 0.57 (0.47;0. 65) < 0.001
Data are shown as median (25
th;7 5
th percentile). All PFT variables except FEV1/FVC are presented as percentage of predicted. P-value refers to Mann-Whitney-U
test.
Abbreviations: DLCO, diffusion capacity of carbon monoxide, FEV1, forced expiratory volume in 1 second, FVC, forced vital capacity, RV, residual volume, TLC,
total lung capacity.
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levels low (62 [49;76] % of predicted) (table 4).
Prognostic capacity of the COPD definitions
During a median follow-up of 4.5 (quartiles 3.9; 5.1)
years, 148 patients experienced at least one episode of a
COPD exacerbation (defined as a 7-10 days boots of
prednisolone use), 67 patients were hospitalized for pul-
monary reasons, and 60 patients died.
A COPD diagnosis according to the expert panel iden-
tified the largest number of patients that experienced
any of the aforementioned events, followed by COPD
according to GOLD and COPD-LLN (see table 5). The
occurrence of outcomes related to the different classifi-
cations of COPD with percentages related to the classifi-
cation of COPD is presented in table 6.
Hazard ratios of COPD yes versus no for the prognos-
tic outcomes for any of the definitions are presented in
table 7. With all COPD definitions, those with COPD
had significantly worse prognostic outcomes as com-
pared to those with ‘no COPD’.
Pulmonary function test predictors of the diagnosis of
COPD, using the expert panel as the reference
From all PFT variables (besides FEV/FVC), FEV1 % pre-
dicted, RV/TLC and DLCO % predicted performed best in
predicting the expert diagnosis of COPD. The c-statistics
of these variables using the expert panel diagnosis of
COPD as the reference were 0.95 (95% CI 0.93-0.97), 0.85
(95% CI 0.81-0.89), and 0.77 (95% CI 0.73-0.82),
respectively.
Addition of FEV1 and RV/TLC to GOLD-COPD and LLN-
COPD
Addition of FEV1 and RV/TLC (both as % predicted) to
the GOLD- or LLN-based definition improved diagnos-
tic test performance significantly. Kappa statistics for
the GOLD definition increased from 0.64 up to 0.83
(p < 0.001) and the number of misdiagnoses decreased
from 69 to 33 (highest kappa statistics seen for 10%
deviation; see Figure 1 for explanation of the algorithm).
For the LLN definitions (Enright/Quanjer/Falaschetti)
the Kappa raised from 0.46/0.53/0.57 up to 0.77/0.79/
Table 3 Diagnostic test performance of GOLD and LLN with the expert panel as the reference test
GOLD LLN: Enright [16] LLN: Quanjer [14] LLN: Falaschetti [17]
COPD prevalence (N) 244 (60%) 142 (35%) 167 (41%) 175(43%)
False positives (N) 33 6 9 9
False negatives (N) 36 111 89 81
Sensitivity 85.4% 55.1% 64.0% 67.2%
Specificity 79.1% 96.2% 94.3% 94.3%
Positive predictive value 86.5% 95.8% 94.6% 94.9%
Negative predictive value 77.6% 57.8% 62.6% 64.8%
Kappa coefficient 0.64 (0.56; 0.71) 0.46 (0.38; 0.53) 0.53 (0.46; 0.60) 0.57 (0.50; 0.64)
P < 0.001 0.006 0.053
COPD prevalence as % or N within the total cohort (N = 405) according to different definitions. P for comparison of  coefficients of GOLD vs LLN.
Table 4 Baseline characteristics of patients with a ‘correct’ and ‘false’ GOLD-COPD diagnosis according to the
reference-test
GOLD-
COPD
FEV1/FVC FEV1
[% pred]
FVC
[% pred]
TLC
[% pred]
RV
[% pred]
RV/TLC
[% pred]
DLCO
[% pred]
Age
[Years]
Pack years
[Years]
True
positive
0.56
(0.46; 0.64)
67
(54; 79)
94
(82; 110)
114
(103; 126)
147
(122; 177)
124
(112; 140)
62
(49; 76)
73
(70; 77)
28.0
(10.6; 52.5)
N = 211 211 211 211 207 207 207 181 211 211
False
positive
0.66
(0.61; 0.68)
98
(94; 107)
119
(108; 133)
113
(104; 120)
119
(107; 135)
103
(94; 109)
78
(70; 91)
72
(69; 78)
3.4
(0; 22.5)
N = 33 33 33 33 33 33 33 33 33 33
True
negative
0.78
(0.74; 0.83)
108
(100; 118)
112
(100; 123)
105
(97; 113)
106
(94; 116)
98
(92; 107)
82
(72; 92)
71
(67; 75)
1.1
(0; 23.8)
N = 125 125 125 125 124 124 124 119 125 125
False
negative
0.74
(0.72; 0.76)
79
(71; 85)
86
(75; 93)
104
(94; 118)
135
(106; 165)
124
(113; 146)
67
(54; 74)
73
(69; 78)
19.1
(0; 40.9)
N = 36 36 36 36 36 36 36 30 36 36
COPD was defined by the GOLD definition and test results were categorized into ‘correct’ or ‘false’ according to the diagnosis of the expert-panel.
FEV1/FVC, FEV1, FVC are given as post-bronchodilator values; TLC, RV and DLCO as pre-bronchodilator values.
Abbreviations: as in table 1.
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117/98/90 to 44/40/39 (highest kappa statistics seen for
all 3 LLN definitions for 5% deviation; see Figure 1 for
explanation of the algorithm).
Discussion
In our study we show that false positive diagnosis of
COPD occurred more often with the GOLD definition,
while false negatives were more common with the LLN
definitions as compared to an expert panel diagnosis as
the reference test. Adding FEV1 and RV/TLC improved
the GOLD and LLN approach, reducing misdiagnosed
COPD by up to 50% depending on the cut-points applied.
The expert panel diagnosis predicted best the occurrence
of exacerbations of COPD, pulmonary hospitalizations,
and all-cause mortality, followed by the GOLD and LLN
definitions.
The choice of a fixed cut-off point for the GOLD-COPD
definition was made for reasons of generalization and sim-
plification [22]. Although even lower FEV1/FVC ratios
than 0.7 can be expected in the elderly without a patholo-
gical correlate, [7] a spirometric test result of > 0.7 does
not necessarily exclude a diagnosis of COPD in these
patients. Especially elderly patients tend to incompletely
empty their lungs during the performance of the FVC
manoeuvre [23], resulting in a lower FVC value and thus
an increased FEV1/FVC ratio, rendering false-negative
COPD diagnoses more likely.
Multiple studies already showed that fewer patients
are diagnosed as COPD positive when LLN definitions
are applied instead of GOLD, especially in the elderly
(e.g., 36 vs. 15% in a healthy Dutch cohort of patients
aged ≥ 50 years) [5,7,9,24,25]. The present study con-
firms the aforementioned differences in prevalence rates
of COPD according to GOLD or LLN. Importantly,
however, all previous studies involved in the discussion
whether LLN or GOLD should be applied, compared
both methods without application of a reference test.
Without a reference, however, it is impossible to answer
which method performs better [11]. This lack of evi-
dence and the resulting diagnostic uncertainties have
not been adequately appreciated. Application of the
LLN will increase the chance of classifying COPD
patients as having no COPD and thus the risk of under-
treatment of especially elderly patients (Figure 2).
The diagnosis of our expert panel was validated
internally and externally. Re-evaluation of 80 cases
(20%) in 2011 by the same panel as in 2001/2003 had a
very good kappa of 0.90. External validation with a
panel including a German pulmonologist and a Dutch
GP with special interest in COPD was somewhat lower
with a kappa of 0.76, which still can be considered as a
good accordance.
Despite a higher number of patients with mild COPD,
the expert panel diagnosis of COPD was highly asso-
ciated with COPD exacerbations, pulmonary hospitaliza-
tions and all-cause deaths, underlining the validity of
the expert panel diagnosis.
As expected, a LLN-based diagnosis of COPD gener-
ated less false positives and more false negatives as
Table 5 Prognostic outcomes according to different COPD definitions within the whole cohort
COPD definition
(N*)
Exacerbations of COPD
(N = 148)
Pulmonary Hospitalizations
(N = 67)
All-cause
Mortality
(N = 60)
Expert COPD (N* = 247) 114/148 (77.0%) 49/67 (73.1%) 50/60 (83.3%)
GOLD COPD (N* = 244) 114/148 (77.0%) 46/67 (68.7%) 43/60 (71.7%)
LLN: Enright [16] (N* = 142) 76/148 (51.4%) 34/67 (50.7%) 32/60 (53.3%)
LLN: Quanjer [14] (N* = 167) 88/148 (59.5%) 37/67 (55.2%) 35/60 (58.3%)
LLN: Falaschetti [17] (N* = 175) 91/148 (61.5%) 37/67 (55.2%) 35/60 (58.3%)
Absolute numbers (%) of clinically relevant outcomes according to the respective definition of COPD. N* corresponds to the number of patients classified as
COPD according to the individual COPD definitions. The denominator corresponds to the absolute number of events.
Table 6 Prognostic outcomes according to different COPD definitions within each “COPD definition”
COPD definition
N*
Exacerbations of COPD
(N = 148)
Pulmonary Hospitalizations
(n = 67)
All-cause
Mortality
(n = 60)
Expert COPD (N* = 247) 114/247 (46.2%) 49/247 (19.8%) 50/247 (20.2%)
GOLD COPD (N* = 244) 114/244 (46.7%) 46/244 (18.9%) 43/244 (17.6%)
LLN: Enright [16] (N* = 142) 76/142 (53.5%) 34/142 (23.9%) 32/142 (22.5%)
LLN: Quanjer [14] (N* = 167) 88/167 (52.7%) 37/167 (22.2%) 35/167 (21.0%)
LLN: Falaschetti [17] (N* = 175) 91/175 (52.0%) 37/175 (21.1%) 35/175 (20.0%)
Absolute numbers (%) of clinically relevant outcomes in patients classified as COPD according to the different definitions. N* corresponds to the number of
patients classified as COPD according to the individual COPD definitions. The denominator corresponds also to the absolute number of individuals within each
COPD definition.
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Page 6 of 9compared to the conventional GOLD definition. The
overall accuracy of LLN was similar or worse than the
conventional GOLD definition when compared to the
expert panel diagnosis of COPD. Misclassifications
occurred mainly in patients with GOLD stage I and II.
Typically, in diagnostic test research there is a trade-
off between specificity and sensitivity (see Figure 2). For
a balanced approach the consequences of false positive
and false negative cases should be assessed. A false posi-
tive result in the case of COPD may lead to over-treat-
ment and therefore avoidable expenses for the health
system. Furthermore, the adverse effects of pulmonary
medication might cause more harm than benefit to
some patients [26-28]. In addition, a false positive diag-
nosis of COPD increases the risk that physician and
patient remain unaware of other possible reasons for the
complaints, such as cardiovascular diseases, notably
heart failure [29].
The effects of a false negative diagnosis is undertreat-
ment of patients with COPD at a point in time when
they probably would benefit most (GOLD stages I and
II). Table 5 summarizes the effect of classifying the pre-
sence or absence of ‘COPD’ according to the different
methods. LLN tends to categorize elderly with mild
obstruction as ‘no COPD’ (high specificity and low sen-
sitivity). In absolute numbers, LLN identified fewer
patients with clinically relevant prognostic events
(COPD exacerbation, hospitalization, mortality) than the
GOLD or panel definition. As a clinical consequence,
fewer elderly patients would receive therapy targeted at
reducing these events, when the clinician would apply
LLN instead of the GOLD or panel diagnoses. Table 7
shows that the prognostic abilities of LLN, GOLD and
panel were compatible with clearly overlapping 95%
confidence intervals of the hazard ratios. Early diagnosis
and identification of false negatives may enable interven-
tion strategies as counseling for smoking cessation and
exercise training when pulmonary compromise is still
mild [30]. Initiation of pharmacotherapy can reduce
symptoms, improve quality of life, and decrease the
number of acute exacerbations [31,32]. Guidelines there-
fore advocate early detection of airflow limitation [4].
Am u l t i p l et e s tr e s u l ta p p r o a c hw i t hi n c o r p o r a t i n g
bodyplethysmographic data seems a reasonable way to
establish a more reliable diagnosis of COPD, although,
we have to consider that bodyplethysmography is costly,
with an average prices of 75 to 200 US Dollars per per-
formance [33].
FEV1 is probably the most important determinant of
obstruction, and RV/TLC is known to be highly and
inversely correlated to FEV1% of predicted [33]. Normal
values of FEV1 and RV/TLC in subjects with a FEV1/
FVC ratio < 0.70 should motivate re-evaluation of a
positive diagnosis of COPD based solely on the conven-
tional GOLD criteria. An approach many pulmonolo-
gists apply in clinical practice. As an alternative, DLCO
could be used instead of RV/TLC, although more miss-
ing and indecisive results with this method were seen in
our analysis and might be generally be expected (data
not shown).
The National Institute for Clinical Excellence (NICE)
acknowledged the importance of FEV1 as distinct para-
meter to diagnose COPD, and defined airflow
Table 7 Prognostic outcomes according to different COPD definitions in univariate Cox regression analysis
COPD definition Exacerbations of COPD
HR (95% CI) P
Hospitalisation for
pulmonary reason
HR (95% CI) P
All-cause
death
HR (95% CI) P
Expert panel (N = 247) 2.94 (1.99;4.31) P < 0.001 2.03 (1.18;3.49) P = 0.010 3.59 (1.82;7.07) P < 0.001
GOLD-COPD (N = 244) 2.92 (1.99;4.28) P < 0.001 1.62 (0.97;2.72) P = 0.067 1.81 (1.03;3.17) P = 0.038
LLN: Enright [16] (N = 142) 2.70 (1.95;3.73) P < 0.001 2.20 (1.36;3.55) P = 0.001 2.28 (1.37;3.78) P = 0.001
LLN: Quanjer [14] (N = 167) 2.97 (2.14;4.14) P < 0.001 2.06 (1.27;3.33) P = 0.003 2.21 (1.32;3.70) P = 0.002
LLN: Falaschetti [17] (N = 175) 2.89 (2.07;4.03) P < 0.001 1.87 (1.15;3.03) P = 0.011 2.02 (1.21;3.38) P = 0.007
Univariate Cox Regression analysis comparing COPD yes versus no diagnosis per definition. N corresponds to the number of patients with COPD according to the
different definitions of COPD.
Abbreviations:
CI, Confidence interval, HR, Hazard ratio, FN, false negative, FP, false positive, TN, true negative, TP, true positive.
Figure 2 Change of the threshold of FEV1/FVC ratio will
change the amount of misdiagnosis in both directions.
Application of the LLN definition in elderly patients which generally
results in FEV1/FVC levels smaller than 0.7 reduces the number of
FP diagnoses but subsequently increases the FN.
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Page 7 of 9obstruction if both the FEV1/FVC ratio is < 0.7 and the
FEV1 < 80% of predicted, and thus ‘starting’ the diagno-
s i so fC O P Df r o mG O L DI Io n w a r d s[ 3 4 ] .A p p l i c a t i o n
of the NICE definition (post-bronchodilator values) in
our cohort as compared to the expert panel diagnosis of
COPD led to very high specificity (99%; only two false
positives) but low sensitivity (66%, 82 false negatives).
Incorporating a second PFT parameter as FEV1 into a
FEV1/FVC-based definition might effectively reduce
false positive test results, however for correction of false
negative results at least a three parameters approach is
needed.
Certain limitations need to be considered in the inter-
pretation of our findings. PFT was only performed once
at baseline, and secular trends could have been missed.
Second, information on graphical PFT results as the
flow volume curve or the flow pressure curve also
enhance the diagnostic ability of the expert panel, but
we could not quantify how much these graphs added to
the final decision of the panel.
Another limitation in our study is incorporation bias
when assessing the added value of other PFT variables
to improve the diagnosis of GOLD or LLN [35]. PFT
parameters play an important role in the diagnosis of
the expert panel. Thus, overoptimism of the diagnostic
performance of PFT variables such as FEV1 and RV/
TLC should be considered. Robust external validation
and accurate cut-off calculations are still needed before
the proposed algorithm of including FEV1 and RV/TLC
in the GOLD or LLN definition may be adopted in rou-
tine practice. Our intention, however, was not to create
a new definition of COPD, but to raise the awareness of
some of the shortcomings of the single fixed cut-off
v a l u eo fF E V / F V C0 . 7a n dt h ea g e - a d j u s t e dL L N
definitions.
In conclusion, both the conventional GOLD criteria
and some of the most frequently used LLN-based diag-
n o s e so fC O P Ds h a r em a j o rs h o r t c o m i n g sa sc o m p a r e d
to the expert panel diagnosis of COPD. While GOLD
definition tends to overdiagnose COPD, LLN-based defi-
nitions tend to underdiagnose COPD in symptomatic
patients. Adding the information on FEV1 and RV/TLC
to the GOLD definition reduced the number of misdiag-
noses substantially for either definition. Further studies
are needed to explore the usefulness of ‘an upgraded’
COPD or LLN diagnosis with determination of the opti-
mal cut-off values for RV/TLC and DLCO.
Abbreviations
BMI: Body mass index; COPD: Chronic obstructive pulmonary disease; DLCO:
Diffusion capacity of carbon monoxide; ECCS European Community for Coal
and Steel; ERS European Respiratory Society; FEV1: Forced expiratory volume
in 1 second; FVC: Forced vital capacity; GOLD Global Initiative for chronic
Obstructive Lung Disease; GP: General practitioner; LLN Lower limit of
normal; NICE National Institute for Clinical Excellence; PFT: Pulmonary
function test; RV: Residual volume; SD Standard deviation; TIA: Transient
ischemic attack; TLC: Total lung capacity; USA United States of America.
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